Ibandronate
Active ingredient: Ibandronate Sodium
In short: Ibandronate Sodium Tablets are indicated for the treatment and prevention of osteoporosis in postmenopausal women. Ibandronate sodium increases bone mineral density (BMD) and reduces the incidence of vertebral fractures.
What is Ibandronate used for?
Ibandronate Sodium Tablets are indicated for the treatment and prevention of osteoporosis in postmenopausal women. Ibandronate sodium increases bone mineral density (BMD) and reduces the incidence of vertebral fractures.
The optimal duration of use has not been determined. The safety and effectiveness of Ibandronate Sodium Tablets for the treatment of osteoporosis are based on clinical data of three years duration. All patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. Patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. Patients who discontinue therapy should have their risk for fracture re-evaluated periodically.
Ibandronate dosage
The dose of Ibandronate Sodium Tablet is one 150 mg tablet taken once monthly on the same date each month.
Instruct Patients to do the following:
• Take Ibandronate Sodium Tablet at least 60 minutes before the first food or drink (other than water) of the day or before taking any oral medication or supplementation, including calcium, antacids, or vitamins to maximize absorption and clinical benefit, . Avoid the use of water with supplements including mineral water because they may have a higher concentration of calcium.
• Swallow Ibandronate Sodium Tablets whole with a full glass of plain water (6 to 8 oz) while standing or sitting in an upright position to reduce the potential for esophageal irritation. Avoid lying down for 60 minutes after taking Ibandronate Sodium Tablet . Do not chew or suck the tablet because of a potential for oropharyngeal ulceration.
• Do not eat, drink anything except plain water, or take other medications for at least 60 minutes after taking Ibandronate Sodium Tablet.
Instruct patients to take supplemental calcium and vitamin D if their dietary intake is inadequate. Avoid the use of calcium supplements within 60 minutes of Ibandronate Sodium Tablet administration because co-administration of Ibandronate Sodium Tablet and calcium may interfere with the absorption of ibandronate sodium
.
If the once-monthly dose is missed, instruct patients to do the following:
• If the next scheduled Ibandronate Sodium Tablet day is more than 7 days away, take one Ibandronate Sodium Tablet 150 mg (ibandronate) in the morning following the date that it is remembered.
• If the next scheduled Ibandronate Sodium Tablet day is only 1 to 7 days away, wait until the subsequent month’s scheduled Ibandronate Sodium Tablet day to take their tablet.
For subsequent monthly doses for both of the above scenarios, instruct patients to return to their original schedule by taking one Ibandronate Sodium Tablet 150 mg (ibandronate) every month on their previous chosen day.
How to take Ibandronate — instructions & advice from the label
“See FDA-approved patient labeling (Medication Guide)”
Instruct patients to read the Medication Guide carefully before taking Ibandronate Sodium Tablets and to re-read it each time the prescription is renewed because it contains important information the patient should know about Ibandronate Sodium Tablets. The Medication Guide also includes the dosing instructions in order to maximize absorption and clinical benefit.
• Ibandronate Sodium Tablet should be taken at least 60 minutes before the first food or drink (other than water) of the day and before taking any oral medication or supplementation including calcium, antacids or vitamins .
• To facilitate delivery to the stomach, and thus reduce the potential for esophageal irritation, Ibandronate Sodium Tablet should be swallowed whole with a full glass of plain water (6 to 8 oz) while the patient is standing or sitting in an upright position. Patients should not lie down for 60 minutes after taking Ibandronate Sodium Tablet.
• Patients should not eat, drink anything except for water, or take other medications for 60 minutes after taking Ibandronate Sodium Tablet. …
Warnings & precautions
Do not take this medicine if: Ibandronate sodium is contraindicated in patients with the following conditions:
• Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia
• Inability to stand or sit upright for at least 60 minutes
• Hypocalcemia
• Known hypersensitivity to ibandronate sodium tablets or to any of its excipients. Cases of anaphylaxis have been reported. .
Ibandronate sodium, like other bisphosphonates administered orally, may cause local irritation of the upper gastrointestinal mucosa. Because of these possible irritant effects and a potential for worsening of the underlying disease, caution should be used when ibandronate sodium is given to patients with active upper gastrointestinal problems (such as known Barrett’s esophagus, dysphagia, other esophageal diseases, gastritis, duodenitis or ulcers).
Esophageal adverse experiences, such as esophagitis, esophageal ulcers and esophageal erosions, occasionally with bleeding and rarely followed by esophageal stricture or perforation, have been reported in patients receiving treatment with oral bisphosphonates. In some cases, these have been severe and required hospitalization. Physicians should therefore be alert to any signs or symptoms signaling a possible esophageal reaction and patients should be instructed to discontinue ibandronate sodium and seek medical attention if they develop dysphagia, odynophagia, retrosternal pain or new or worsening heartburn.
The risk of severe esophageal adverse experiences appears to be greater in patients who lie down after taking oral bisphosphonates and/or who fail to swallow it with the recommended full glass (6 to 8 oz) of water, and/or who continue to take oral bisphosphonates after developing symptoms suggestive of esophageal irritation. …
Ibandronate side effects
The following clinically significant adverse drug reactions are described elsewhere in the labeling:• Upper Gastrointestinal Adverse Reactions
• Hypocalcemia and Mineral Metabolism
• Musculoskeletal
• Jaw Osteonecrosis
• Atypical Fractures Including Femoral Fractures
• Severe Renal Impairment
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Treatment and Prevention of Postmenopausal Osteoporosis
Monthly DosingThe safety of ibandronate sodium 150 mg once monthly in the treatment of postmenopausal osteoporosis was assessed in a two year trial which enrolled 1583 patients aged 54 to 81 years, with 395 patients exposed to ibandronate sodium 2.5 mg daily and 396 exposed to ibandronate sodium 150 mg monthly. Patients with active or significant pre-existing gastrointestinal disease were excluded from this trial. Patients with dyspepsia or concomitant use of non-steroidal anti-inflammatory drugs, proton pump inhibitors and H2 antagonists were included in this study. All patients received 500 mg calcium plus 400 international units vitamin D supplementation daily.
After one year, the incidence of all-cause mortality was 0.3% in both the ibandronate sodium 2.5 mg daily group and the ibandronate sodium 150 mg monthly group. …
Drug interactions
Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of ibandronate sodium. Therefore, instruct patients to take ibandronate sodium at least 60 minutes before any oral medications, including medications containing multivalent cations (such as antacids, supplements or vitamins). Also, patients should wait at least 60 minutes after dosing before taking any other oral medications .
Because aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with ibandronate sodium.
In healthy volunteers, co-administration with ranitidine resulted in a 20% increased bioavailability of ibandronate, which was not considered to be clinically relevant .
Bisphosphonates are known to interfere with the use of bone-imaging agents. Specific studies with ibandronate have not been performed.
About this medicine
Ibandronate sodium is a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption. The chemical name for ibandronate sodium is 3-(N-methyl-N-pentyl) amino-1-hydroxypropane-1,1-diphosphonic acid, monosodium salt, monohydrate with the molecular formula C9H22NO7P2Na·H2O and a molecular weight of 359.24. Ibandronate sodium is a white- to off-white powder. It is freely soluble in water and practically insoluble in organic solvents. Ibandronate sodium has the following structural formula:
Ibandronate sodium is available as a yellow colored capsule shaped 150 mg film-coated tablet for once-monthly oral administration. One 150 mg film-coated tablet contains 168.75 mg ibandronate monosodium monohydrate, equivalent to 150 mg free acid. Ibandronate sodium tablet also contains the following inactive ingredients: lactose monohydrate, povidone, crospovidone, microcrystalline cellulose, colloidal silicon dioxide, and sodium stearyl fumarate. The tablet film coating contains hypromellose, titanium dioxide, polyethylene glycol, and iron oxide yellow. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 6ca94cce-a2bb-421f-bd8f-6b14bc2bd985. Read the full official label on DailyMed.
Related medicines
Levothyroxine Ergocalciferol Estradiol Ethinyl Estradiol and Norethindrone Alendronate Testosterone Thyroid Norethindrone